To further verify this conclusion in vivo, T24 cells overexpressing IGF2BP3 or the control group were injected under the skin of nude mice to establish a xenograft tumor model, and to observe whether the expression of IGF2BP3 affects the sensitivity of bladder cancer to cisplatin and whether palbociclib enhances the sensitivity of bladder cancer to cisplatin in vivo. The gene discussed is IGF2BP3; the disease is urinary bladder cancer.